Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 1.00 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15015503 | 0.82 | EPHX2 (0.70) | EPHX2 | |
| SCHEMBL4084600 | 0.79 | EPHX2 (0.65) | EPHX2TSHRHSD11B1 | |
| SCHEMBL4113319 | 0.79 | EPHX2 (0.64) | EPHX2NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL4107706 | 0.78 | EPHX2 (0.63) | EPHX2EPHX1SMN1; SMN2HSD11B1 | |
| SCHEMBL19808478 | 0.77 | EPHX2 (0.66) | EPHX2HSD11B1 | |
| SCHEMBL6032606 | 0.76 | EPHX1 (0.85) | EPHX2P2RX7EPHX1NPC1TP53 | |
| SCHEMBL11149799 | 0.75 | EPHX2 (0.60) | EPHX2P2RX7NPC1TSHRRAB9A | |
| SCHEMBL2752153 | 0.75 | EPHX1 (0.97) | EPHX2EPHX1NPC1TP53TSHR | |
| Hydrochloric Acid SCHEMBL11159933 | 0.74 | EPHX2 (0.58) | EPHX2P2RX7SMN1; SMN2HSD11B1 | |
| SCHEMBL1420825 | 0.74 | EPHX2 (0.68) | EPHX2P2RX7EPHX1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960352-B1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | claimed |
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | claimed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | claimed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | claimed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | claimed |
| EP-1960352-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2008-08-27 | — | — | EP | claimed |
| EP-1801098-A1 | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors | Merck Sante (FR) | 2007-06-27 | — | — | EP | claimed |
| WO-2007068330-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2007-06-21 | — | — | WO | claimed |
| EP-1960352-B1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-1960352-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1801098-A1 | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors | Merck Sante (FR) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007068330-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | EPHX2 597/4885P2RX7 4146/4885EPHX1 294/4885 |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | EPHX2 503/4885P2RX7 4170/4885EPHX1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.